P38α MAPK mediates 17β-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells

Journal of Cellular Physiology

Volumn 227, Issue 11, 2012, Pages 3648-3660

  Hsu, Hsi Hsien ^a,b   Liu, Chung Jung ^c   Shen, Chia Yao ^d   Chen, Yi Jyun ^e   Chen, Li Mien ^f   Kuo, Wu Hsien ^g   Lin, Yueh Min ^h,i   Chen, Ray Jade ^j   Tsai, Chang Hai ^k   Tsai, Fuu Jen ^e   Huang, Chih Yang ^e,k  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d MEIHO UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f Taichung General Hospital   (Taiwan)

^g TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^h CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

ⁱ JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^j TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^k ASIA UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIN A; CYCLIN D1; CYCLIN E; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PLASMINOGEN ACTIVATOR INHIBITOR; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE PLASMINOGEN ACTIVATOR; UO 126; UROKINASE;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR BIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN A; CYCLIN D1; CYCLIN E; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84864083373     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24072     Document Type: Article

References (51)

1. Baker EA, Leaper DJ. 2003. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: Relationship to tumour pathology. Eur J Cancer 39: 981-988.
2. Baker EA, Bergin FG, Leaper DJ. 2000. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 53: 307-312.
3. Berger DH. 2002. Plasmin/plasminogen system in colorectal cancer. World J Surg 26: 767-771.
4. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, Kung HF, Colburn NH, Sun Y. 1996. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17: 1805-1811.
5. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. 1995. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87: 517-523.
6. Campbell-Thompson M, Lynch IJ, Bhardwaj B. 2001. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 61: 632-640.
7. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G, Feifel G, Zeitz M, Stallmach A. 2001. Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. Int J Colorectal Dis 16: 133-140.
8. Cheng YC, Chen LM, Chang MH, Chen WK, Tsai FJ, Tsai CH, Lai TY, Kuo WW, Huang CY, Liu CJ. 2009. Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 325: 15-23.
9. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E. 2004. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350: 991-1004.
10. Collins HM, Morris TM, Watson SA. 2001. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: Relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 84: 1664-1670.
11. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295: 2387-2392.
12. Ellerbroek SM, Stack MS. 1999. Membrane associated matrix metalloproteinases in metastasis. Bioessays 21: 940-949.
13. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. 2003. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 17: 139-147.
14. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. 1989. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA 86: 8207-8211.
15. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. 1997. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
16. Greenwald P. 1992. Colon cancer overview. Cancer 70: 1206-1215.
17. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ. 1998. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128: 705-712.
18. Habiro A, Tanno S, Koizumi K, Izawa T, Nakano Y, Osanai M, Mizukami Y, Okumura T, Kohgo Y. 2004. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 316: 71-77.
19. Hartwell LH, Kastan MB. 1994. Cell cycle control and cancer. Science 266: 1821-1828.
20. Hashimoto K, Morishige K, Sawada K, Ogata S, Tahara M, Shimizu S, Sakata M, Tasaka K, Kimura T. 2007. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo. Biochem Biophys Res Commun 356: 72-77.
21. Hsiao YC, Kuo WH, Chen PN, Chang HR, Lin TH, Yang WE, Hsieh YS, Chu SC. 2007. Flavanone and 2′-OH flavanone inhibit metastasis of lung cancer cells via down-regulation of proteinases activities and MAPK pathway. Chem Biol Interact 167: 193-206.
22. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. 2007. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 67: 4320-4327.
23. Hsu HH, Hu WS, Lin YM, Kuo WW, Chen LM, Chen WK, Hwang JM, Tsai FJ, Liu CJ, Huang CY. 2011. JNK suppression is essential for 17beta-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. J Biomed Sci 18: 61.
24. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. 2007. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27: 609-630.
25. Hur K, Kim JR, Yoon BI, Lee JK, Choi JH, Oh GT, Kim DY. 2000. Overexpression of cyclin D1 and cyclin E in 1, 2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis. J Vet Sci 1: 121-126.
26. Jacobs ET, Thompson PA, Martinez ME. 2007. Diet, gender, and colorectal neoplasia. J Clin Gastroenterol 41: 731-746.
27. Jemal A, Thomas A, Murray T, Thun M. 2002. Cancer statistics, 2002. CA Cancer J Clin 52: 23-47.
28. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. 2004. Cancer statistics, 2004. CA Cancer J Clin 54: 8-29.
29. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. 2005. Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
30. Jeziorska M, Haboubi NY, Schofield PF, Ogata Y, Nagase H, Woolley DE. 1994. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colorectal Dis 9: 141-148.
31. Katzenellenbogen JA, Katzenellenbogen BS. 1996. Nuclear hormone receptors: Ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3: 529-536.
32. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC. 2006. Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207: 729-734.
33. Lai TY, Chen LM, Lin JY, Tzang BS, Lin JA, Tsai CH, Lin YM, Huang CY, Liu CJ, Hsu HH. 2010. 17beta-estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. Mol Cell Biochem 342: 63-70.
34. Li YY, McTiernan CF, Feldman AM. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46: 214-224.
35. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, Yeh P, Perricaudet M, Lu H. 2001. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 12: 515-526.
36. Liotta LA, Stetler-Stevenson WG. 1991. Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51: 5054s-5059s.
37. 2+/ROS-mediated suppression of ERK/c-fos pathway and activation of p38 MAPK/c-jun pathway. J Cell Physiol 224: 775-785.
38. Liu CJ, Lo JF, Kuo CH, Chu CH, Chen LM, Tsai FJ, Tsai CH, Tzang BS, Kuo WW, Huang CY. 2009. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med 13: 3655-3667.
39. Maeda K, Chung YS, Kang SM, Ogawa M, Onoda N, Nakata B, Nishiguchi Y, Ikehara T, Okuno M, Sowa M. 1997. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74: 310-315.
40. Marino M, Galluzzo P, Ascenzi P. 2006. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7: 497-508.
41. Milkiewicz M, Kelland C, Colgan S, Haas TL. 2006. Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells. J Cell Physiol 208: 229-237.
42. Mook OR, Frederiks WM, Van Noorden CJ. 2004. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89.
43. Roeb E, Dietrich CG, Winograd R, Arndt M, Breuer B, Fass J, Schumpelick V, Matern S. 2001. Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer 92: 2680-2691.
44. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. 2003. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82: 184-193.
45. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB. 1997. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 28: 285-309.
46. Weng MS, Ho YS, Lin JK. 2005. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: Involvement of p38 mitogen-activated protein kinase. Biochem Pharmacol 69: 1815-1827.
47. Wong NA, Morris RG, McCondochie A, Bader S, Jodrell DI, Harrison DJ. 2002. Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol 197: 128-135.
48. Wu CH, Liu JY, Wu JP, Hsieh YH, Liu CJ, Hwang JM, Lee SD, Chen LM, Chang MH, Kuo WW, Shyu JC, Tsai JH, Huang CY. 2005. 17beta-estradiol reduces cardiac hypertrophy mediated through the up-regulation of PI3K/Akt and the suppression of calcineurin/NF-AT3 signaling pathways in rats. Life Sci 78: 347-356.
49. Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, Kim JY, Lee YC, Kim JM, Park JI, Park HD, No ZS, Lim K, Hwang BD, Kim YS. 2004. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res 10: 4517-4526.
50. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, Tamm M, Black JL, Roth M. 2006. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: A comparison between mesothelioma and mesothelial cells. J Cell Physiol 207: 540-552.
51. Zucker S, Vacirca J. 2004. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23: 101-117.